skip to main content

S. 164: Advancing Education on Biosimilars Act of 2021

Call or Write Congress

A bill to educate health care providers and the public on biosimilar biological products, and for other purposes.

The bill’s titles are written by its sponsor.

Sponsor and status

Margaret “Maggie” Hassan

Sponsor. Junior Senator for New Hampshire. Democrat.

Read Text »
Last Updated: Mar 3, 2021
Length: 6 pages
Introduced
Feb 2, 2021
117th Congress (2021–2023)
Status

Passed Senate (House next) on Mar 3, 2021

This bill passed in the Senate on March 3, 2021 and goes to the House next for consideration.

Prognosis
4% chance of being enacted according to Skopos Labs (details)
Source

History

Feb 2, 2021
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

Mar 3, 2021
 
Passed Senate (House next)

The bill was passed in a vote in the Senate. It goes to the House next. The vote was by Unanimous Consent so no record of individual votes was made.

If this bill has further action, the following steps may occur next:
 
Passed House

 
Signed by the President

S. 164 is a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

Bills numbers restart every two years. That means there are other bills with the number S. 164. This is the one from the 117th Congress.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“S. 164 — 117th Congress: Advancing Education on Biosimilars Act of 2021.” www.GovTrack.us. 2021. March 5, 2021 <https://www.govtrack.us/congress/bills/117/s164>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.